OTCMKTS:AOXG

Aoxing Pharmaceutical Competitors

$0.01
0.00 (0.00 %)
(As of 04/19/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.01
Now: $0.01
$0.01
50-Day Range
$0.01
MA: $0.01
$0.03
52-Week Range
$0.00
Now: $0.01
$0.05
VolumeN/A
Average Volume69,745 shs
Market Capitalization$990,730.00
P/E RatioN/A
Dividend YieldN/A
Beta3.26

Competitors

Aoxing Pharmaceutical (OTCMKTS:AOXG) Vs. ABMC, AMBS, AKRXQ, VGLS, INNVD, and IMNPQ

Should you be buying AOXG stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Aoxing Pharmaceutical, including American Bio Medica (ABMC), Amarantus BioScience (AMBS), Akorn (AKRXQ), VG Life Sciences (VGLS), Innovus Pharmaceuticals (INNVD), and Immune Pharmaceuticals (IMNPQ).

American Bio Medica (OTCMKTS:ABMC) and Aoxing Pharmaceutical (OTCMKTS:AOXG) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, valuation, earnings, analyst recommendations, profitability and dividends.

Valuation & Earnings

This table compares American Bio Medica and Aoxing Pharmaceutical's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
American Bio Medica$3.65 million1.03$-680,000.00N/AN/A
Aoxing PharmaceuticalN/AN/AN/AN/AN/A

Aoxing Pharmaceutical has lower revenue, but higher earnings than American Bio Medica.

Profitability

This table compares American Bio Medica and Aoxing Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
American Bio Medica-18.99%N/A-35.34%
Aoxing PharmaceuticalN/AN/AN/A

Analyst Ratings

This is a summary of current ratings and target prices for American Bio Medica and Aoxing Pharmaceutical, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
American Bio Medica0000N/A
Aoxing Pharmaceutical0000N/A

Volatility & Risk

American Bio Medica has a beta of -1.45, suggesting that its share price is 245% less volatile than the S&P 500. Comparatively, Aoxing Pharmaceutical has a beta of 3.26, suggesting that its share price is 226% more volatile than the S&P 500.

Summary

Aoxing Pharmaceutical beats American Bio Medica on 3 of the 4 factors compared between the two stocks.

Aoxing Pharmaceutical (OTCMKTS:AOXG) and Amarantus BioScience (OTCMKTS:AMBS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

Insider and Institutional Ownership

0.0% of Amarantus BioScience shares are owned by institutional investors. 17.8% of Aoxing Pharmaceutical shares are owned by insiders. Comparatively, 10.3% of Amarantus BioScience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Aoxing Pharmaceutical and Amarantus BioScience's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aoxing PharmaceuticalN/AN/AN/AN/AN/A
Amarantus BioScienceN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of current recommendations for Aoxing Pharmaceutical and Amarantus BioScience, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aoxing Pharmaceutical0000N/A
Amarantus BioScience0000N/A

Volatility & Risk

Aoxing Pharmaceutical has a beta of 3.26, indicating that its share price is 226% more volatile than the S&P 500. Comparatively, Amarantus BioScience has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.

Profitability

This table compares Aoxing Pharmaceutical and Amarantus BioScience's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aoxing PharmaceuticalN/AN/AN/A
Amarantus BioScienceN/AN/AN/A

Summary

Aoxing Pharmaceutical beats Amarantus BioScience on 2 of the 3 factors compared between the two stocks.

Akorn (OTCMKTS:AKRXQ) and Aoxing Pharmaceutical (OTCMKTS:AOXG) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, profitability, analyst recommendations, valuation and risk.

Profitability

This table compares Akorn and Aoxing Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Akorn-54.01%-5.13%-0.49%
Aoxing PharmaceuticalN/AN/AN/A

Analyst Recommendations

This is a summary of current ratings and recommmendations for Akorn and Aoxing Pharmaceutical, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Akorn0000N/A
Aoxing Pharmaceutical0000N/A

Volatility & Risk

Akorn has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500. Comparatively, Aoxing Pharmaceutical has a beta of 3.26, meaning that its stock price is 226% more volatile than the S&P 500.

Institutional and Insider Ownership

0.1% of Akorn shares are owned by institutional investors. 3.9% of Akorn shares are owned by company insiders. Comparatively, 17.8% of Aoxing Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Akorn and Aoxing Pharmaceutical's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Akorn$682.43 million0.01$-226,770,000.00N/AN/A
Aoxing PharmaceuticalN/AN/AN/AN/AN/A

Aoxing Pharmaceutical has lower revenue, but higher earnings than Akorn.

Summary

Aoxing Pharmaceutical beats Akorn on 5 of the 7 factors compared between the two stocks.

Aoxing Pharmaceutical (OTCMKTS:AOXG) and VG Life Sciences (OTCMKTS:VGLS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Aoxing Pharmaceutical and VG Life Sciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aoxing Pharmaceutical0000N/A
VG Life Sciences0000N/A

Volatility and Risk

Aoxing Pharmaceutical has a beta of 3.26, meaning that its share price is 226% more volatile than the S&P 500. Comparatively, VG Life Sciences has a beta of 1.61, meaning that its share price is 61% more volatile than the S&P 500.

Valuation & Earnings

This table compares Aoxing Pharmaceutical and VG Life Sciences' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aoxing PharmaceuticalN/AN/AN/AN/AN/A
VG Life SciencesN/AN/AN/AN/AN/A

Profitability

This table compares Aoxing Pharmaceutical and VG Life Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aoxing PharmaceuticalN/AN/AN/A
VG Life SciencesN/AN/AN/A

Summary

Aoxing Pharmaceutical beats VG Life Sciences on 1 of the 1 factors compared between the two stocks.

Innovus Pharmaceuticals (OTCMKTS:INNVD) and Aoxing Pharmaceutical (OTCMKTS:AOXG) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, risk, profitability, valuation and earnings.

Profitability

This table compares Innovus Pharmaceuticals and Aoxing Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Innovus Pharmaceuticals-34.51%-682.54%-78.57%
Aoxing PharmaceuticalN/AN/AN/A

Valuation and Earnings

This table compares Innovus Pharmaceuticals and Aoxing Pharmaceutical's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Innovus Pharmaceuticals$23.99 million0.00$-8,280,000.00($4.16)N/A
Aoxing PharmaceuticalN/AN/AN/AN/AN/A

Aoxing Pharmaceutical has lower revenue, but higher earnings than Innovus Pharmaceuticals.

Insider and Institutional Ownership

10.4% of Innovus Pharmaceuticals shares are held by institutional investors. 16.4% of Innovus Pharmaceuticals shares are held by company insiders. Comparatively, 17.8% of Aoxing Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Risk & Volatility

Innovus Pharmaceuticals has a beta of 2.89, meaning that its stock price is 189% more volatile than the S&P 500. Comparatively, Aoxing Pharmaceutical has a beta of 3.26, meaning that its stock price is 226% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for Innovus Pharmaceuticals and Aoxing Pharmaceutical, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Innovus Pharmaceuticals0000N/A
Aoxing Pharmaceutical0000N/A

Summary

Aoxing Pharmaceutical beats Innovus Pharmaceuticals on 5 of the 7 factors compared between the two stocks.

Aoxing Pharmaceutical (OTCMKTS:AOXG) and Immune Pharmaceuticals (OTCMKTS:IMNPQ) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, dividends, earnings, institutional ownership and profitability.

Risk & Volatility

Aoxing Pharmaceutical has a beta of 3.26, suggesting that its share price is 226% more volatile than the S&P 500. Comparatively, Immune Pharmaceuticals has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500.

Valuation & Earnings

This table compares Aoxing Pharmaceutical and Immune Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aoxing PharmaceuticalN/AN/AN/AN/AN/A
Immune PharmaceuticalsN/AN/AN/AN/AN/A

Analyst Ratings

This is a breakdown of recent recommendations for Aoxing Pharmaceutical and Immune Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aoxing Pharmaceutical0000N/A
Immune Pharmaceuticals0000N/A

Profitability

This table compares Aoxing Pharmaceutical and Immune Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aoxing PharmaceuticalN/AN/AN/A
Immune PharmaceuticalsN/AN/AN/A

Summary

Aoxing Pharmaceutical beats Immune Pharmaceuticals on 1 of the 1 factors compared between the two stocks.


Aoxing Pharmaceutical Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
American Bio Medica logo
ABMC
American Bio Medica
0.5$0.09flat$3.75 million$3.65 million0.00News Coverage
Gap Down
Amarantus BioScience logo
AMBS
Amarantus BioScience
0.0$0.01flat$3.63 millionN/A0.00Gap Down
AKRXQ
Akorn
0.1$0.03flat$3.60 million$682.43 million-0.01
VG Life Sciences logo
VGLS
VG Life Sciences
0.0$0.01flat$3.36 millionN/A0.00Gap Up
INNVD
Innovus Pharmaceuticals
0.6N/AN/A$2.90 million$23.99 million-0.72Gap Down
Immune Pharmaceuticals logo
IMNPQ
Immune Pharmaceuticals
0.0$0.14flat$2.88 millionN/A0.00
Capstone Therapeutics logo
CAPS
Capstone Therapeutics
0.8$36.01flat$2.85 million$2 million0.00
RespireRx Pharmaceuticals logo
RSPI
RespireRx Pharmaceuticals
0.5$0.04flat$2.82 millionN/A-0.09News Coverage
Gap Up
VVUSQ
VIVUS
0.6$0.12flat$2.10 million$69.76 million-0.04
IMUCD
ImmunoCellular Therapeutics
0.0$0.45flat$1.87 millionN/A0.00Gap Up
NSPX
Inspyr Therapeutics
0.5$0.01flat$1.83 millionN/A0.00Gap Up
Earth Science Tech logo
ETST
Earth Science Tech
0.5$0.04flat$1.78 million$530,000.000.00Gap Up
Boston Therapeutics logo
BTHE
Boston Therapeutics
0.5$0.02flat$1.70 million$20,000.00-0.77
ImmunoCellular Therapeutics logo
IMUC
ImmunoCellular Therapeutics
0.0$0.45flat$1.57 millionN/A0.00News Coverage
Gap Up
Cardax logo
CDXI
Cardax
0.0$1.95flat$1.55 million$710,000.000.00High Trading Volume
Gap Up
MLNTQ
Melinta Therapeutics
0.2$0.11flat$1.51 million$96.43 million0.00
HSTC
HST Global
0.8$0.26flat$1.36 millionN/A0.00Gap Down
WWHC
W World
0.8$4.90flat$1.33 millionN/A0.00
Achaogen logo
AKAOQ
Achaogen
0.6$0.03flat$1.29 million$8.73 million0.00Gap Up
Propanc Biopharma logo
PPCB
Propanc Biopharma
0.7$0.22flat$1.17 millionN/A0.00Decrease in Short Interest
Gap Down
Cotinga Pharmaceuticals logo
COTQF
Cotinga Pharmaceuticals
0.4$0.05flat$1.12 millionN/A-0.57Upcoming Earnings
TetraLogic Pharmaceuticals logo
TLOG
TetraLogic Pharmaceuticals
0.5$0.04flat$978,000.00N/A0.00
AOLS
Aeolus Pharmaceuticals
0.8$0.01flat$928,000.00N/A0.00Gap Down
ATRX
Adhera Therapeutics
0.0$0.07flat$872,000.00$250,000.000.00Gap Up
Anthera Pharmaceuticals logo
ANTH
Anthera Pharmaceuticals
0.5$0.06flat$865,000.00N/A0.00
PXYN
Praxsyn
0.6$0.00flat$763,000.00N/A0.00
SPHS
Sophiris Bio
0.1$0.02flat$739,000.00N/A0.00Gap Down
Argos Therapeutics logo
ARGSQ
Argos Therapeutics
0.6$0.05flat$572,000.00$1.90 million0.00
Sienna Biopharmaceuticals logo
SNNAQ
Sienna Biopharmaceuticals
0.5$0.03flat$547,000.00N/A0.00
TRPXD
Therapix Biosciences
0.0$9.20flat$460,000.00N/A0.00High Trading Volume
BSPM
Biostar Pharmaceuticals
0.0$0.15flat$399,000.00N/A0.00
SKVI
Skinvisible
0.7$0.08flat$376,000.00$40,000.000.00
EPRSQ
EPIRUS Biopharmaceuticals
0.5$0.02flat$366,000.00N/A0.00
Spotlight Innovation logo
STLT
Spotlight Innovation
0.5$0.01flat$343,000.00N/A0.00
ProMetic Life Sciences logo
PFSCF
ProMetic Life Sciences
0.5$5.47flat$338,000.00$36.55 million0.00Gap Up
WDBG
Woodbrook Group
0.0$1.60flat$224,000.00N/A0.00
ROSGQ
Rosetta Genomics
0.0$0.10flat$183,000.00N/A0.00Gap Down
PZRXQ
PhaseRx
0.2$0.02flat$175,000.00N/A0.00
OREXQ
Orexigen Therapeutics
0.4$0.01flat$100,000.00$33.71 million0.00Gap Up
MetaStat logo
MTST
MetaStat
0.0$0.01flat$82,000.00$20,000.000.00
AXMP
AXM Pharma
0.2$0.00flat$81,000.00N/A0.00
ALSE
Alseres Pharmaceuticals
0.0$6.00flat$36,000.00N/A0.00
BOPH
Bohai Pharmaceuticals Group
0.5$0.00flat$20,000.00N/A0.00
Immune Therapeutics logo
IMUN
Immune Therapeutics
0.6$0.01flat$7,000.00$110,000.000.00Gap Up
Acusphere logo
ACUS
Acusphere
0.0$0.04flat$0.00N/A0.00Gap Down
Affymax logo
AFFY
Affymax
0.6$0.10flat$0.00N/A0.00Gap Up
AOBI
American Oriental Bioengineering
0.4$1.50flat$0.00N/A0.00
ARYX
ARYx Therapeutics
0.0$0.01flat$0.00N/A0.00
AHROQ
AtheroNova
0.0$0.01flat$0.00N/A0.00
CBPI
China Botanic Pharmaceutical
0.0$0.07flat$0.00N/A0.00
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.